Shots:
The collaboration will use Brainomix’s e-ILD technology, an AI-based program & will focus on quantitative analysis of imaging data in the P-II study to evaluate the safety, tolerability, and efficacy of BBT-877 (novel autotaxin inhibitor) for the treatment of IPF
The collaboration enables Bridge to produce supplemental efficacy data from clinical studies on IPF patients, based on a combination of imaging technology & expertise
Automated AI-driven quantitative imaging is designed to enhance trial design, increase a favorable treatment response & accelerate the translation of new treatments into clinical practice
Ref: PRNewswire | Image: Brainomix
